U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H19ClN2S
Molecular Weight 318.8658
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHLORPROMAZINE

SMILES

CN(C)CCCN1c2ccccc2Sc3ccc(cc31)Cl

InChI

InChIKey=ZPEIMTDSQAKGNT-UHFFFAOYSA-N
InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C17H19ClN2S
Molecular Weight 318.8658
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Chlorpromazine is a psychotropic agent indicated for the treatment of schizophrenia. It also exerts sedative and antiemetic activity. Chlorpromazine has actions at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Chlorpromazine has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity. Chlorpromazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects). Additionally, Chlorpromazine is a weak presynaptic inhibitor of Dopamine reuptake, which may lead to (mild) antidepressive and antiparkinsonian effects. Chlorpromazine has being marketed under the trade names Thorazine and Largactil among others. Chlorpromazine is used for treating certain mental or mood disorders (eg, schizophrenia), the manic phase of manic-depressive disorder, anxiety and restlessness before surgery, the blood disease porphyria, severe behavioral and conduct disorders in children, nausea and vomiting, and severe hiccups.

Originator

Curator's Comment:: Chlorpromazine was synthesized in December 1951 in the laboratories of Rhône-Poiulenc, and became available on prescription in France in November 1952.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
THORAZINE

Approved Use

For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.

Launch Date

-3.82319985E11
Primary
THORAZINE

Approved Use

For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.

Launch Date

-3.82319985E11
Primary
THORAZINE

Approved Use

For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.

Launch Date

-3.82319985E11
Primary
THORAZINE

Approved Use

For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.

Launch Date

-3.82319985E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
37.9 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4.31 ng/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
11.9 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
135 ng × h/mL
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
247 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
27.8 ng × h/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
81.8 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.1 h
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
11.05 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5.48 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
9.52 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
unknown, unknown
CHLORPROMAZINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
75 mg 1 times / day multiple, intravenous
Highest studied dose
Dose: 75 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
unhealthy, 52 years (range: 36.5-65.6 years)
Health Status: unhealthy
Condition: agitation
Age Group: 52 years (range: 36.5-65.6 years)
Sex: M+F
Sources:
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, Elderly Patients
Health Status: unhealthy
Condition: Dementia-Related Psychosis
Age Group: Elderly Patients
Sources:
Other AEs: Adverse event...
25 mg 1 times / day multiple, intramuscular
Dose: 25 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, Elderly Patients
Health Status: unhealthy
Condition: Dementia-Related Psychosis
Age Group: Elderly Patients
Sources:
Other AEs: Adverse event...
AEs

AEs

AESignificanceDosePopulation
Adverse event grade 5
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, Elderly Patients
Health Status: unhealthy
Condition: Dementia-Related Psychosis
Age Group: Elderly Patients
Sources:
Adverse event grade 5
25 mg 1 times / day multiple, intramuscular
Dose: 25 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, Elderly Patients
Health Status: unhealthy
Condition: Dementia-Related Psychosis
Age Group: Elderly Patients
Sources:
Overview

Overview

OverviewOther

Drug as perpetrator​Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia. Theoretical implications for potency differences among neuroleptics.
1975 Aug 21
Altered pilocarpine- or chlorpromazine-induced catalepsy after long-term treatment with cholinergic drugs.
1979 Nov
Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor.
1992 Apr 10
[A case of neuroleptic malignant syndrome with acute renal failure].
1992 Nov
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.
1992 Sep
Impaired extrapyramidal function caused by the targeted disruption of retinoid X receptor RXRgamma1 isoform.
1999 Apr
[Intractable vomiting, convulsions and megaloblastic anemia: anamnesis, key to diagnosis].
1999 Jul 3
Tardive dystonia induced by risperidone.
1999 Jun
Macrophage Fcgamma receptors expression is altered by treatment with dopaminergic drugs.
1999 Mar
Block of rat brain recombinant SK channels by tricyclic antidepressants and related compounds.
2000 Jul 28
Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.
2000 Oct
Chlorpromazine induces apoptosis in activated human lymphoblasts: a mechanism supporting the induction of drug-induced lupus erythematosus?
2000 Sep
Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction.
2001 Jan
Chlorpromazine-induced cholestatic liver disease with ductopenia.
2001 Jul
Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs.
2001 Jul
Combination of benzo[a]phenothiazines with acyclovir against herpes simplex virus.
2001 Jul
Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines.
2001 Mar
Iatrogenic cardiopulmonary arrest during pediatric sedation with meperidine, promethazine, and chlorpromazine.
2001 Oct
[Models of drug treatment in the attention deficit disorder with hyperactivity].
2002 Feb
[The effect of microwaves on the bioelectric brain activity].
2002 Sep-Oct
Dual action of oestrogens on the mouse constitutive androstane receptor.
2003 Dec 1
Scopolamine-induced convulsions in fasted mice after food intake: determination of blood glucose levels, [3H]glutamate binding kinetics and antidopaminergic drug effects.
2003 Feb
Acute massive pulmonary thromboembolism associated with risperidone and conventional phenothiazines.
2003 Jan
Copper-stimulated endocytosis and degradation of the human copper transporter, hCtr1.
2003 Mar 14
Mechanism of C2-toxin inhibition by fluphenazine and related compounds: investigation of their binding kinetics to the C2II-channel using the current noise analysis.
2003 Oct 24
UVA activated 8-MOP and chlorpromazine inhibit release of TNF-alpha by post-transcriptional regulation.
2004 Apr
Effects of lipopolysaccharide and chlorpromazine on glucocorticoid receptor-mediated gene transcription and immunoreactivity: a possible involvement of p38-MAP kinase.
2004 Dec
Spasmodic dysphonia, a rare form of tardive dystonia, induced by low-dose risperidone?
2004 Mar
Antipsychotics increase microtubule-associated protein 2 mRNA but not spinophilin mRNA in rat hippocampus and cortex.
2004 May 1
The phenothiazine drugs inhibit hERG potassium channels.
2005
Intraoperative preparation of the radial artery for coronary artery bypass grafting.
2005
Invited review: fluphenazine augments retinal oxidative stress.
2005 Aug
Effects of chlorpromazine with and without UV irradiation on gene expression of HepG2 cells.
2005 Aug 4
A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system.
2005 Feb
New inhibitors of the Tat-TAR RNA interaction found with a "fuzzy" pharmacophore model.
2005 Jun
Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients.
2005 Mar 7
Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates.
2005 Nov
The effects of desmethylimipramine on cyclic AMP-stimulated gene transcription in a model cell system.
2005 Sep 1
Antipsychotic drugs inhibit the human corticotropin-releasing-hormone gene promoter activity in neuro-2A cells-an involvement of protein kinases.
2006 Apr
Effect of chlorpromazine on bone sialoprotein (BSP) gene transcription.
2006 Apr 15
Retinoid-mediated stimulation of steroid sulfatase activity in myeloid leukemic cell lines requires RARalpha and RXR and involves the phosphoinositide 3-kinase and ERK-MAP kinase pathways.
2006 Feb 1
Frequency of high-risk use of QT-prolonging medications.
2006 Jun
Patents

Sample Use Guides

Usual Adult Dose for Psychosis HOSPITALIZED PATIENTS: Acute Schizophrenia/Manic States: Oral: -Usual dose: 500 mg/day orally -Maximum dose: 2000 mg/day Parenteral: -Usual dose: 25 mg IM once, with a subsequent 25 to 50 mg injection in 1 hour if necessary -Maintenance dose: 400 mg IM every 4 to 6 hours until the patient is controlled Prompt Control of Severe Symptoms: Oral: -Usual dose: After an initial IM dose, 25 to 50 mg orally 3 times a day Parenteral: -Usual dose: 25 mg IV once, repeated in 1 hour if necessary Less Acutely Disturbed: Oral: -Initial dose: 25 mg orally 3 times a day -Usual dose: 400 mg/day Usual Adult Dose for Schizophrenia HOSPITALIZED PATIENTS: Acute Schizophrenia/Manic States: Oral: -Usual dose: 500 mg/day orally -Maximum dose: 2000 mg/day Parenteral: -Usual dose: 25 mg IM once, with a subsequent 25 to 50 mg injection in 1 hour if necessary -Maintenance dose: 400 mg IM every 4 to 6 hours until the patient is controlled Prompt Control of Severe Symptoms: Oral: -Usual dose: After an initial IM dose, 25 to 50 mg orally 3 times a day Parenteral: -Usual dose: 25 mg IV once, repeated in 1 hour if necessary Less Acutely Disturbed: Oral: -Initial dose: 25 mg orally 3 times a day -Usual dose: 400 mg/day
Route of Administration: Other
In Vitro Use Guide
Chlorpromazine inhibited the serotonin2-mediated excitation of the interneurons of rat piriform cortex with an IC50 of 14 uM.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:00:05 UTC 2021
Edited
by admin
on Fri Jun 25 21:00:05 UTC 2021
Record UNII
U42B7VYA4P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHLORPROMAZINE
HSDB   INN   MART.   MI   ORANGE BOOK   USP   VANDF   WHO-DD  
INN  
Official Name English
CHLORPROMAZINUM
HPUS  
Common Name English
ESMIND
Common Name English
CHLORPROMAZINE [MART.]
Common Name English
2-CHLORO-10-(3-(DIMETHYLAMINO)PROPYL)PHENOTHIAZINE
Systematic Name English
CHLORPROMAZINUM [HPUS]
Common Name English
NSC-226514
Code English
SANOPRON
Common Name English
CHLORPROMAZINE [VANDF]
Common Name English
CHLORPROMAZINE [INN]
Common Name English
J2.794D
Code English
SKF-2601A
Code English
CHLORPROMAZINE [HSDB]
Common Name English
CHLORPROMAZINE [USP MONOGRAPH]
Common Name English
NSC-167745
Code English
PROPAPHENIN
Common Name English
10H-PHENOTHIAZINE-10-PROPANAMINE, 2-CHLORO-N,N-DIMETHYL-
Systematic Name English
CPZ
Common Name English
3-(2-CHLORO-10H-PHENOTHIAZIN-10-YL)-N,N-DIMETHYLPROPAN-1-AMINE
Systematic Name English
LARGACTILOTHIAZINE
Common Name English
WINTERMIN
Common Name English
FENACTIL
Common Name English
CHLORPROMAZINE [ORANGE BOOK]
Common Name English
THORAZINE
Brand Name English
NOVOMAZINA
Common Name English
CHLORPROMAZINE [MI]
Common Name English
AMINAZINE
Common Name English
CHLORPROMAZINE [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-ATC N05AA01
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
NDF-RT N0000175746
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
NDF-RT N0000007544
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
WHO-VATC QN05AA01
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
NDF-RT N0000007544
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
NCI_THESAURUS C29710
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 24.1
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
NDF-RT N0000007544
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
NCI_THESAURUS C740
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
LIVERTOX 196
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL71
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
CAS
50-53-3
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
DRUG BANK
DB00477
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
IUPHAR
83
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
DRUG CENTRAL
621
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
HSDB
3033
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
NCI_THESAURUS
C367
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-045-8
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
EVMPD
SUB06208MIG
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
EPA CompTox
50-53-3
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
PUBCHEM
2726
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
INN
183
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
MERCK INDEX
M3461
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY Merck Index
LACTMED
Chlorpromazine
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
RXCUI
2403
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY RxNorm
FDA UNII
U42B7VYA4P
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
EVMPD
SUB01255MIG
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
MESH
D002746
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
WIKIPEDIA
CHLORPROMAZINE
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
BINDING PROTEIN->LIGAND
chlorpromazine displayed an approximately 1:1 [drug:AGP] binding stoichiometry; DETERMINED BY ITC
BINDING
Kd
METABOLIC ENZYME -> INHIBITOR
IC50
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
Metabolizing reaction by CYP2D6: N-demethylation Pharmacological action: Phenothiazine antipsychotic
SUBSTRATE
Unidentified
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE ACTIVE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC